Glyoxylate

Glyoxylate

SCHEMBL377124

O=CC(=O)[O-].O=CC(=O)[O-].[Zn+2]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.36
CA4 P22748 3/20 0.36
FAHD1 Q6P587 1/20 0.36
CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glyoxylate SCHEMBL94446 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL11209424 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL3031126 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL3588289 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL314561 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL5357985 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL3704926 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL2495812 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL3593610 0.91 CA1 (0.36) CA1CA4FAHD1CA9
Glyoxylate SCHEMBL3596612 0.91 CA1 (0.36) CA1CA4FAHD1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021195540-A1 CANNABINOID BASED COMPOSITION FOR MITIGATION OF VIRAL EFFECTS RADIENT TECHNOLOGIES INNOVATIONS INC. (CA) 2021-09-30 WO claimed
WO-2010009275-A1 METHODS OF TREATING INFLAMMATION INTEGRITAS PHARMA, INC (US) 2010-01-21 WO claimed
EP-1416926-A4 ZINC CONTAINING COMPOSITIONS FOR ANTI-VIRAL USE SMITH JEFFREY B (US) 2009-03-04 EP claimed
US-7462369-B2 Anti-viral compositions and methods of making and using the anti-viral compositions Smith, Jeffrey B. (US) 2008-12-09 US claimed
US-20080274209-A1 METHODS OF TREATING INFLAMMATION INTEGRITAS PHARMA, INC. 2008-11-06 US claimed
US-6855341-B2 Anti-viral compositions and methods of making and using the anti-viral compositions SMITH JEFFREY B (US) 2005-02-15 US claimed
US-20050003020-A1 Anti-viral compositions and methods of making and using the anti-viral compositions SMITH JEFFREY B (US) 2005-01-06 US claimed
EP-1416926-A2 ZINC CONTAINING COMPOSITIONS FOR ANTI-VIRAL USE Smith, Jeffrey B. (US) 2004-05-12 EP claimed
US-20040086575-A1 Anti-viral compositions and methods of making and using the anti-viral compositions SMITH JEFFREY B (US) 2004-05-06 US claimed
US-6730329-B1 TREATING LESIONOUS SYMPTOMS TOPICALLY WITH ACTIVE MATERIAL SALT AND ANTIOXIDANT SMITH JEFFREY B (US) 2004-05-04 US claimed
WO-2002098339-A2 ZINC CONTAINING COMPOSITIONS FOR ANTI-VIRAL USE SMITH JEFFREY B (US) 2002-12-12 WO claimed
US-6475526-B1 Zinc containing compositions for anti-viral use SMITH JEFFREY B (US) 2002-11-05 US claimed
EP-0761806-B1 Polyurea-thickened grease composition LUBRIZOL CORP (US) 2001-10-31 EP claimed
US-6214778-B1 OILS AND LUBRICANTS WITH THICKENERS AND ZINC OVERBASED SALTS THE LUBRIZOL CORPORATION 2001-04-10 US claimed
EP-0761806-A1 Polyurea-thickened grease composition The Lubrizol Corporation (US) 1997-03-12 EP claimed
US-4407818-A HERPES SIMPLEX VIRUS BIO-SYSTEMS RESEARCH, INC. (US) 1983-10-04 US claimed
JP-9104889-A None JP disclosed
CN-110650944-B Silica-based zinc catalysts, their preparation and use in the alkoxycarbonylation of amines 科思创德国股份有限公司 2022-07-19 CN disclosed
EP-0049671-A1 New metal oxyalkylates, pharmaceutical compositions containing the same and process for preparing the same BioSystems Research, Inc. (US) 1982-04-14 EP disclosed
US-4268683-A ZIN OR TIN COMPOUNDS AS ACID CATALYSTS THE DOW CHEMICAL COMPANY (US) 1981-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080274209-A1 METHODS OF TREATING INFLAMMATION MPO, SOD1, MMP8 CA1 2983/4885CA4 1891/4885FAHD1 2709/4885
US-20040086575-A1 Anti-viral compositions and methods of making and using the anti-viral compositions ZC3HAV1, ZC3HAV1L, SOD3 CA1 2436/4885CA4 1492/4885FAHD1 1350/4885
US-20050003020-A1 Anti-viral compositions and methods of making and using the anti-viral compositions ZC3HAV1, ZC3HAV1L, SOD3 CA1 2436/4885CA4 1492/4885FAHD1 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.